Showing 1051-1060 of 2066 results for "".
- Colloidal Oatmeal Moisturizer in Managing Skin Microbiota: Studyhttps://practicaldermatology.com/news/colloidal-oatmeal-moisturizer-in-managing-skin-microbiota-study/2471650/A new in vitro study suggests a moisturizer containing colloidal oatmeal, patented filaggrin technology, niacinamide, and tocopheryl acetate selectively inhibits the growth and adhesion of Staphylococcus aureus (S. aureus) while promoting Staphylococcus epidermidis
- Zeroing in on What Causes Melanoma to Spread to the Brainhttps://practicaldermatology.com/news/zeroing-in-on-what-causes-melanoma-to-spread-to-the-brain/2462160/More than half of patients with advanced melanoma will see the disease spread to the brain, where it rapidly progresses, often leading to death in only three to four months. Researchers in Moffitt Cancer Center’s
- Hemoglobin Discovered in the Epidermishttps://practicaldermatology.com/news/hemoglobin-discovered-in-the-epidermis/2462140/Hemoglobin is present in the epidermis, according to new research that sheds light on the skin's protective properties. For the first time,reesearchers discovered the hemoglobin α protein in human and mouse keratinocytes of the epidermis
- Smart Ring May Objectively Measure Scratching Intensityhttps://practicaldermatology.com/news/smart-ring-may-objectively-measure-scratching-intensity/2462015/A new wearable device may objectively measure the intensity of scratching. Akhil Padmanabha, a PhD student in Carnegie Mellon University's (CMU)
- Wristbands May Be Home to E. coli, Staphhttps://practicaldermatology.com/news/wristbands-may-be-home-to-e-coli-staphylococcus/2461937/Common wristbands can be ‘hotbed’ for harmful bacteria including E. coli, staphylococcus, according to new research. Researchers from Florida Atlantic University’s Charles E. Schmidt Colleg
- Arcutis’ ZORYVE Now in Preferred Position on National Formularies for CVS Caremarkhttps://practicaldermatology.com/news/arcutis-zoryve-now-in-preferred-position-on-national-formularies-for-cvs-caremark/2461868/Arcutis Biotherapeutics, Inc.’s ZORYVE (roflumilast) cream 0.3% for the treatment of plaque psoriasis, including intertriginous psoriasis in adults and adolescents, is now covered as a preferred tier product on national formularies for CVS Caremar
- Bimekizumab Update: FDA Still Reviewing UCB's BLAhttps://practicaldermatology.com/news/bimekizumab-update-fda-still-reviewing-ucbs-bla/2461813/The U.S. Food & Drug Administration (FDA) is still reviewing UCB’s Biologics License Application (BLA) for bimekizumab for moderate to severe plaque psoriasis, UCB reports. UCB previously
- DataDerm in Action: AAD Launches Project to Improve Outcomes for GPP Patientshttps://practicaldermatology.com/news/aad-launches-project-to-improve-outcomes-for-gpp-patients/2461804/The American Academy of Dermatology is launching a new project to develop educational resources to improve the evaluation, diagnosis, and treatment of patients with generalized pustular psoriasis (GPP). The AAD is working with Boehringer Ingelheim and using OM1’s data aggregation
- News You Can Use: SID Announces New Research Grant Program Focusing on Type 2 Inflammationhttps://practicaldermatology.com/news/news-you-can-use-sid-announces-new-research-grant-program-focusing-on-type-2-inflammation/2461767/The Society for Investigative Dermatology’s (SID) new research grant program, The SID Type 2 Inflammation Innovation Awards, is open now and the deadline is August 31, 2023
- AOBiome’s B244 Eases Eczema Symptoms, Helps Tame Itchhttps://practicaldermatology.com/news/aobiomes-b244-eases-eczema-symptoms-helps-tame-itch/2461723/AOBiome Therapeutics, Inc.’s B244 treatment demonstrated significant improvements in eczema severity and itch reduction The Phase 2b clinical data is published in